ABSTRACT
The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Because there is no common genetic alteration causing resistance to venetoclax in chronic lymphocytic leukemia (CLL) and B-cell lymphoma, we asked if epigenetic events might be involved in venetoclax resistance. Therefore, we employed whole-exome sequencing, methylated DNA immunoprecipitation sequencing, and genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 screening to investigate venetoclax resistance in aggressive lymphoma and high-risk CLL patients. We identified a regulatory CpG island within the PUMA promoter that is methylated upon venetoclax treatment, mediating PUMA downregulation on transcript and protein level. PUMA expression and sensitivity toward venetoclax can be restored by inhibition of methyltransferases. We can demonstrate that loss of PUMA results in metabolic reprogramming with higher oxidative phosphorylation and adenosine triphosphate production, resembling the metabolic phenotype that is seen upon venetoclax resistance. Although PUMA loss is specific for acquired venetoclax resistance but not for acquired MCL1 resistance and is not seen in CLL patients after chemotherapy-resistance, BAX is essential for sensitivity toward both venetoclax and MCL1 inhibition. As we found loss of BAX in Richter's syndrome patients after venetoclax failure, we defined BAX-mediated apoptosis to be critical for drug resistance but not for disease progression of CLL into aggressive diffuse large B-cell lymphoma in vivo. A compound screen revealed TRAIL-mediated apoptosis as a target to overcome BAX deficiency. Furthermore, antibody or CAR T cells eliminated venetoclax resistant lymphoma cells, paving a clinically applicable way to overcome venetoclax resistance.
Subject(s)
Hematologic Neoplasms , Leukemia, Lymphocytic, Chronic, B-Cell , Lymphoma, Large B-Cell, Diffuse , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Myeloid Cell Leukemia Sequence 1 Protein/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , bcl-2-Associated X Protein/metabolism , Drug Resistance, Neoplasm/genetics , Apoptosis Regulatory Proteins/genetics , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Lymphoma, Large B-Cell, Diffuse/pathology , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/genetics , Epigenesis, GeneticABSTRACT
Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1-69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09-3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.
Subject(s)
Cell Transformation, Neoplastic , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma/pathology , Adult , Aged , Aged, 80 and over , Biopsy , Cell Transformation, Neoplastic/genetics , Disease Progression , Female , Genetic Variation , Germany , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Lymphoma/etiology , Lymphoma/mortality , Lymphoma/therapy , Male , Middle Aged , Neoplasm Grading , Neoplasm Staging , Prognosis , Survival Analysis , Time Factors , Young AdultSubject(s)
Immunotherapy/adverse effects , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Lymphadenopathy/etiology , Neoplasm, Residual/drug therapy , Abdomen/pathology , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols , Disease Progression , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Lymph Nodes/pathology , Male , Middle Aged , Prognosis , Proportional Hazards Models , Prospective Studies , Treatment OutcomeSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Adult , Aged , Aged, 80 and over , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Female , Gender Identity , Humans , Immunotherapy/methods , Male , Middle Aged , Treatment OutcomeABSTRACT
Chronic lymphocytic leukemia (CLL) mainly affects older people: the median age at diagnosis is > 70 years. Elderly patients with CLL are heterogeneous with regard both to the biology of their disease and aging. Following the diagnosis of CLL in an elderly individual, careful risk assessment is essential when treatment options are evaluated. This includes not only clinical staging and evaluation of disease-specific prognostic biomarkers such as 17p deletion and TP53 mutation, but also of comorbidities, physical capacity, nutritional status, cognitive capacity, ability to perform activities of daily living and social support. Comorbidity scoring and geriatric assessment tools are helpful in achieving such multidimensional evaluation in a systematic manner. The introduction of new drugs including novel monoclonal antibodies and kinase inhibitors offers enhanced opportunities for the treatment of elderly patients with CLL. This position paper of a Task Force of the International Society of Geriatric Oncology (SIOG) reviews currently available evidence relevant to such patients. All types of elderly patient (i.e. chronological age > 65-70 years) are considered, from robust (fit) to vulnerable (unfit) to the terminally ill. Among the topics covered are the following: (i) the relationship between chronological age, prognosis and survival, (ii) assessment of biological aging, (iii) biological age as a determinant of treatment feasibility and tolerance and (iv) tailoring of both first and further-line treatment to the circumstances of the individual patient.
Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Aged , Aged, 80 and over , Disease Management , Geriatric Assessment , Humans , Immunotherapy , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , Medical Oncology , Neoplasm Staging , Prognosis , Risk Assessment , Treatment OutcomeABSTRACT
This study aimed to assess the frequency of and the contributing factors for second primary malignancies (SPMs) and Richter's transformations (RTs) following first-line treatment of chronic lymphocytic leukemia within four phase II/III trials of the GCLLSG evaluating fludarabine (F) vs F+cyclophosphamide (FC), chlorambucil vs F, FC without or with rituximab, and bendamustine+R (BR). Among 1458 patients, 239 (16.4%) experienced either an SPM (N=191) or a RT (N=75). Solid tumors (N=115; 43.2% of all second neoplasias) appeared most frequently, followed by RTs (N=75; 28.2%). Patients showed a 1.23-fold increased risk of solid tumors in comparison to the age-matched general population from the German cancer registry. Age>65 (hazard ratio (HR) 2.1; P<0.001), male sex (HR 1.7; P=0.01), co-morbidities (HR 1.6; P=0.01) and number of subsequent treatments⩾1 (HR 12.1; P<0.001) showed an independent adverse prognostic impact on SPM-free survival. Serum thymidine kinase>10 U/l at trial enrollment (HR 3.9; P=0.02), non-response to first-line treatment (HR 3.6; P<0.001) and number of subsequent treatments⩾1 (HR 30.2; P<0.001) were independently associated with increased risk for RT.
Subject(s)
Cell Transformation, Neoplastic/chemically induced , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Neoplasms, Second Primary/drug therapy , Adult , Aged , Aged, 80 and over , Bendamustine Hydrochloride/administration & dosage , Bendamustine Hydrochloride/therapeutic use , Case-Control Studies , Chlorambucil/administration & dosage , Chlorambucil/therapeutic use , Cyclophosphamide/administration & dosage , Cyclophosphamide/therapeutic use , Disease-Free Survival , Female , Germany , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , Male , Middle Aged , Neoplasms, Second Primary/mortality , Registries , Risk Assessment , Risk Factors , Vidarabine/administration & dosage , Vidarabine/analogs & derivatives , Vidarabine/therapeutic useABSTRACT
BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western hemisphere and mainly affects elderly patients. No curative treatment is currently available for this disease. TREATMENT: Advanced disease is treated according to the patients' fitness and comorbidity burden as well as according the presence of high risk genetic factors in CLL cells. The detection of del(17p) and/or TP53 gene mutations reflects a very unfavorable prognosis and refractoriness to chemotherapy (very high risk CLL). In physically fit patients without high comorbidity burden and without very high risk prognostic factors, chemoimmunotherapy containing fludarabine, cyclophosphamide, and the CD20 antibody rituximab (FCR) is standard therapy because this regimen has been shown to improve overall survival. In patients with significant comorbidity burden, a less intense chemoimmunotherapy regimen should be administered consisting of the alkylating agent chlorambucil plus CD20 antibody. In very high risk patients, kinase inhibitors blocking the signaling transduction pathway of the B cell receptor have been approved since 2014. The same substances are also approved in relapsed CLL. However, in relapsed CLL repetitive administration of chemoimmunotherapy is still an alternative treatment option, especially if the first remission was longer lasting (> 24 months). Allogeneic hematopoietic stem cell transplantation in very high risk CLL or early relapsed disease has become less important than in the past. In some patients considering the risk of the transplantation versus the risk of failing to respond to the new treatment option, this procedure might still be the treatment of choice in order to achieve long-lasting remissions. CONCLUSION: In the choice of treatment for patients with CLL, several factors must be considered. Because of the broad spectrum of treatment options, therapy within a clinical study is still the best treatment option.